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Abstract
Objective: Hot ﬂushes and night sweats (HFNS) are experienced by up to 80% of prostate cancer patients
undergoing androgen deprivation therapy (ADT). This study evaluates the effects of a guided self-help
cognitive behavioural therapy (CBT) intervention on HFNS problem-rating (primary outcome), HFNS
frequency, mood and health-related quality of life (secondary outcomes) in patients undergoing ADT.
Methods: Patients reporting treatment-induced HFNS were randomly assigned to CBT (n= 33) or
treatment as usual (TAU) (n= 35), stratiﬁed for cancer type. The CBT intervention included a booklet,
CD plus telephone contact during a 4-week period. Validated self-report questionnaires were com-
pleted at baseline, 6 weeks and 32 weeks after randomisation. The primary outcome was HFNS prob-
lem rating (perceived burden of HFNS) at 6 weeks after randomisation. Potential moderators and
mediators were examined. Data analysis was conducted on a modiﬁed intention-to-treat basis.
Results: Compared with TAU, CBT signiﬁcantly reduced HFNS problem rating (adjusted mean dif-
ference: 1.33, 95% CI 2.07 to 0.58; p= 0.001) and HFNS frequency (12.12, 95% CI 22.39 to
1.84; p= 0.02) at 6 weeks. Improvements were maintained at 32 weeks, but group differences did not
reach signiﬁcance. There were signiﬁcant reductions in negative HFNS Beliefs and Behaviours follow-
ing CBT, but not in mood or quality of life.
Conclusions: Guided self-help CBT appears to be a safe and effective brief treatment for men who
have problematic HFNS following prostate cancer treatments. Further research might test the efﬁcacy
of the intervention in a multicentre trial.
© 2015 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
Introduction
Prostate cancer is the most common cancer among men in
the United Kingdom and the second leading cause of cancer
related death in men in the Western world [1]. Androgen
deprivation therapy (ADT) is prescribed to inhibit cancer
progression [2] but is associated with debilitating side ef-
fects, including hot ﬂushes and night sweats (HFNS), that
affect up to 80% of men having ADT [3,4]. HFNS are not
well understood; reductions in androgen levels are believed
to alter the function of brain neurotransmitters, leading to
disruption of the thermoregulatory system in the hypothala-
mus [4,5]. If left untreated, HFNS are associated with sleep
disturbance, distress and reduced quality of life [6,7], and
reduced treatment adherence [4,5]. The symptoms tend to
be frequent [8,9] and can persist for several years [10].
There are few safe and effective treatments for men with
HFNS. A systematic review of treatments for HFNS in
prostate cancer patients concluded that diethylstilbestrol,
megestrol acetate and medroxyprogesterone are the most
effective treatments, but all have side-effects that are not
well tolerated [4]. With an increasing number of prostate
cancer patients being diagnosed [11], there is a pressing
need for safe, acceptable and effective treatments to help
prostate cancer survivors manage HFNS.
There is evidence that cognitive behavioural therapy
(CBT) is a safe and effective intervention for reducing
the impact of HFNS and improving psychosocial func-
tioning for menopausal women [12] and breast cancer sur-
vivors [13,14]. This relatively brief intervention is
effective when delivered in groups and in a guided self-
help format [12–15], and is based on a cognitive model
of HFNS [16]. To our knowledge CBT has not yet been
investigated in prostate cancer patients undergoing ADT
who are experiencing troublesome HFNS.
MANCAN is a randomised controlled trial of guided
self-help CBT compared with treatment as usual (TAU).
We hypothesised that guided self-help CBT would be
more effective than TAU in reducing HFNS problem-
rating (the extent to which HFNS are bothersome and in-
terfere with life) [17,18]. Secondary outcomes include
the effects on HFNS frequency, sternal skin conductance
monitoring [19], mood and quality of life. The trial was
funded by Prostate Cancer UK and registered with the
© 2015 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
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UK Clinical Research Network (UKCRN; Trial ID:
10904). Ethical approval was obtained from South East
London 2 Research Ethics Subcommittee, reference:
11/LO/1114. The authors have no conﬂicts of interests.
Methods
Design and participants
Guided self-help CBT and TAU control group were com-
pared in a randomised controlled trial. The study design is
described in the trial protocol [20]. Prostate cancer pa-
tients were recruited by nurse specialists and medical staff
from oncology and urology clinics in London, UK, be-
tween April 2012 and October 2013. Inclusion criteria
were: English-speaking men over 18 years old, undergo-
ing ADT and having problematic HFNS [score>2 on
the Hot Flush Rating Scale (HFRS) [21] for at least
1 month and a minimum weekly frequency of 10]. Exclu-
sion criteria were: undergoing current radiation therapy,
chemotherapy and having medical/psychiatric conditions
that would affect ability to participate.
Procedures
Potentially eligible patients were screened by telephone
(by ES); those meeting the criteria were sent study infor-
mation and baseline questionnaires. Following consent
and return of questionnaires, they attended a short clinical
interview (with ES), and the Sternal Skin Conductance
(SSC) monitor (see measures) was ﬁtted for 48 h; at the
end of the interview they were informed of their group al-
location (CBT or TAU) (see Figure 1).
At a second assessment interview 6 weeks later (with
OY) (post-treatment), participants completed question-
naires, reported any health or medication changes in the
previous 6 weeks and wore the SSC monitor again for
48 h. At 32 weeks after randomisation (6 months follow-
up), postal questionnaires were completed. At the end of
the study, TAU participants were offered the guided self-
help CBT off trial.
Randomisation and blinding: Computer software
(Rand.exe version 6) was used to assign men randomly
to the CBT or TAU groups, stratifying for cancer type
(i.e. local or locally advanced vs. metastatic). A re-
searcher (OY) generated the randomised allocation list
in sealed envelopes at the beginning of the trial. The pa-
tients and the clinical psychologist (ES) could not be
blind to group allocation; however, the researcher (OY)
remained blind to group allocation throughout the trial,
carried out 6-week and 32-week assessments and per-
formed all data entry. To check whether the researcher
was successfully masked, he estimated which group par-
ticipants had been allocated to after the post-treatment as-
sessment. Masking was reasonably successful with the
allocation of 61% being correctly identiﬁed and equal
proportions from CBT and TAU groups. An independent
researcher (EG), also masked to group allocations, per-
formed the statistical analyses.
The intervention: The guided self-help CBT treatment,
based on interventions developed by Hunter and col-
leagues [12,13,22,23], is a 4-week intervention consisting
of a booklet [20] containing:
i) information about causes of HFNS, the CBT model
and factors affecting HFNS, such as modifying trig-
gers, e.g. caffeine (Week 1),
ii) cognitive therapy for overly negative thoughts and
beliefs about HFNS, and behavioural strategies, e.g.
using paced breathing and relaxation, to reduce stress
and manage HFNS (Week 2),
iii) CBT strategies for managing sleep and NS (Week 3),
iv) suggestions for maintaining changes in the context of
prostate cancer (Week 4).
The intervention which was effective for women with
HFNS was adapted for men, being informed by a qualita-
tive study [24], and was piloted on 12 prostate cancer sur-
vivors who provided feedback on content and how much
guidance they required, for example the term ‘hot sweats’
was preferred to ‘hot ﬂushes’.
At the end of the assessment those randomised to CBT
were given the booklet and a CD with relaxation/paced
breathing exercises by a clinical psychologist (ES). Guid-
ing consisted of a telephone call (average 30 min; range
20–40 min) from the clinical psychologist 2 weeks into
treatment to provide support and discuss individual goals
and progress. TAU included access to clinical staff, and
cancer information and support services, which provided
information and advice about HFNS.
Measures
Sociodemographic and clinical information were obtained
from baseline questionnaires and the clinical interview.
Health economics questions, adapted from Beecham &
Knapp [25], included number of consultations at primary
and secondary care and treatments used at post-treatment
and follow-up.
Primary outcome was HFNS problem-rating at 6 weeks
post-randomisation using the Hot Flush Rating Scale
(HFRS) [21]; problem-rating or interference is associated
with help-seeking and quality of life [17] and is recom-
mended as the most appropriate outcome measure in clin-
ical trials [18]. HFNS problem-rating score is the mean of
three items (assessing the extent to which ﬂushes are prob-
lematic, distressing and interfere with daily life) rated on
10-point scales where higher scores indicate more bother-
some HFNS. A change of 2 points is considered clinically
relevant in studies of women [12,13]. At baseline, internal
consistency was high (Cronbach alpha=0.87).
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Secondary outcomes included: HFNS problem-rating
(HFRS) at 32 weeks; depression and anxiety, as assessed
by the Hospital Anxiety and Depression Scale (HADS)
[26]; HFNS weekly frequency in the past week, as
assessed by the HFRS [21]; quality of life using the
EORTC QLQ-C30 [27] and the EORTC QLQ-PR25
[28] prostate cancer-speciﬁc measure at 6 and 32 weeks.
Possible moderators included age, marital status, level
of education, ethnicity, cancer type, BMI, as well as the
Constructed Meaning Scale (CMS) [29], the Emotional
Control subscale of the Barriers to Help Seeking Scale
[30], the Somatosensory Ampliﬁcation Scale [31] and
Revised Life Orientation Test (LOT-R) [32]. Potential
mediators included the Hot Flush Beliefs and Behaviour
Scale-for Men scale (HFBBS), developed to assess
men’s cognitive appraisals (beliefs) and behaviours in re-
lation to their HFNS [33] with three subscales (Negative
HFNS beliefs/behaviours, Calm acceptance and
Humour/openness, scored 1–6) and frequency of HFNS
using 48-h ambulatory SSC monitoring [19,34,35].
Questions about self-efﬁcacy and treatment expectations
were asked prior to randomisation.
Figure 1. CONSORT diagram showing patient ﬂow through the trial CBT= cognitive behavioural treatment, TAU= treatment as usual,
HFRS =Hot Flush Rating Scale
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Adherence to CBT was measured by the number of
booklet chapters read and the number of times
relaxation/paced breathing were practised each week, re-
corded at the end of treatment. Adverse events were re-
corded in both groups.
Statistical analysis
A total sample size of 50 (25 in each group) was needed to
provide 90% power to detect a clinically signiﬁcant differ-
ence in mean HFNS problem rating of 2 points, for the
comparison of CBT to TAU at 6 weeks post-
randomisation, allowing for baseline value (estimated to
have a mean of 5 and SD of 2.4) and a HFNS problem rat-
ing baseline-to-outcome correlation of 0.4 on analysis of
covariance with two-sided 5% signiﬁcance levels. Analy-
ses were conducted on a modiﬁed intention-to-treat basis;
missing values were replaced by the average scores of
completed items, in the same scale for each individual, pro-
vided that at least 50% of the items in that scale had been
completed. Analyses of covariance were carried out for
each variable separately, comparing baseline scores with
(a) 6-week and (b) 32-week scores, with group (CBT vs.
TAU) as ﬁxed factor and baseline scores as covariates
and Bonferroni adjustment for multiple comparisons. Sta-
tistical analyses are reported with adjusted mean differ-
ences (standard errors; SE), and two-sided 95% CIs.
SPSS (version 18.0) was used for all statistical analyses.
Results
One hundred and ﬁfteen men expressed interest in the study
and 68 met inclusion criteria and were randomised (Figure 1).
Withdrawal rates were minimal at 6 weeks, and complete data
were available for 66 participants for the primary outcomemea-
sure (HFNS problem-rating). Baseline demographics and clini-
cal characteristics were broadly similar in both treatment groups
(Table 1). The sample had a mean age of 69 years, range 49 to
83 years. They tended to be mainly of white ethnicity
(74%), married/cohabiting (74%), unemployed/retired
(78%) and 48% of men had received education beyond
16 years. Comorbidity was common; additional medical
conditions included cardiovascular (e.g. high blood pres-
sure 44.2%), haematological (e.g. cholesterol, diabetes
32.6%) or musculoskeletal (e.g. joint pain 16.3%) prob-
lems. Cancer diagnosis included localised (50%), locally
advanced (19%) and metastatic cancer (31%) (Table 1).
On average the men had been on their current ADT regime
for 16 months (range 2–74 months). Baseline anxiety and
depression scores (HADs) were 5.17 (SD=5.17) and 4.10
(4.10), respectively (25% scored above the cut-off for
depression and 20.6% for anxiety) and Global QOL
(EORTC) was 69.19 (SD=17.23).
At baseline HFNS were frequent with a weekly average
of 54.47 (SD=41.34), range 9 to 280, average duration of
4 (range 2 to 10) min and were rated as moderately prob-
lematic, with average scores of 4.68/10 (SD=2.20).
Primary outcome
Therewas a signiﬁcant difference between groups in the pri-
mary outcome, HFNS problem rating, at 6 weeks after
randomisation (adjusted mean difference of 1.33, 95%
CI2.07 to0.58; p=0.001) with a greater reduction from
baseline in the CBT group compared to the TAU group and
a large effect size (Table 2, Figure 2). The change in prob-
lem rating from baseline was 1.81 (SD 1.94) in the CBT
group, compared with 0.57 (SD 1.74) in TAU group,
representing to a 40% reduction in the CBT group and a
12% reduction in the TAU group; 41% of the CBT group
had a two-point reduction in HFNS problem rating com-
pared to 23% of those allocated to TAU.
Secondary outcomes
There was a signiﬁcant difference between groups in
HFNS frequency at 6 weeks (adjusted mean difference
12.12, 95% CI 22.39 to 1.84; p=0.02) with
greater reductions from baseline in the CBT group com-
pared to the TAU group (Figure 3), with a 36% reduc-
tion in the CBT group and 16% for TAU, and a
medium effect size (Table 2). At 32 weeks the CBT
group maintained their improvements in HFNS problem
rating (CBT 41% and TAU 31% reductions from base-
line) and frequency (CBT 42% and TAU 20% reduc-
tions from baseline), but group differences were not
signiﬁcant. When HFNS were considered separately,
there were signiﬁcant group differences in frequency of
hot ﬂushes at 32 weeks (Table 2). No signiﬁcant group
differences were observed for depressed mood, anxiety
(HADS) or quality of life (EORTC QLQ-C30 Global
QOL) at 6 or 32 weeks (Table 2).
CBT was more effective than TAU in reducing HFNS
problem rating regardless of BMI (normal vs.
overweight/obese), educational level (16 years or less vs.
more than 16 years) or cancer type (locally and locally ad-
vanced vs. metastatic). There were too few numbers in each
category to analyse ethnicity (white vs. non-white) or mari-
tal status. The group difference in the primary outcome,
HFNS problem rating at 6 weeks, remained signiﬁcant
(adjusted mean difference of 1.38, 95% CI 2.16 to
0.60; p=0.001) when we adjusted for baseline HADs
scores, cancer type, age, BMI, educational level and em-
ployment. Baseline self-efﬁcacy and treatment expectations,
CMS, EC, SAS and optimism (LOT-R) (Table 1) did not
moderate HFNS problem-rating outcomes at 6 weeks.
HFNS beliefs and behaviours
There were signiﬁcant group differences in HFNS Beliefs
and Behaviour subscales (see Table 2), the CBT group
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reporting less negative HFNS Bel/Beh about hot ﬂushes
(adjusted mean difference 0.92, 95% CI 1.34 to
0.51; p=0.0001) and more Humour and Openness
(0.56, 95% CI 0.10 to 1.01; p=0.02) compared to the
TAU group 6 weeks after randomisation. Reduction (more
than one point difference) in negative HFNS Bel/Beh
(adjusted mean difference 1.61 CI 2.49 to 0.73;
p=0.001) was associated with improvement in HFNS
problem rating at 6 weeks. This effect was not signiﬁcant
for Humour and Openness (0.10 CI 0.91 to 1.11).
SSC monitoring
Forty-four men wore the SSC monitor; at 6 weeks there
was little change in 48-h rate of HFNS measured by ster-
nal skin conductance, but there was considerable variabil-
ity in response (Table 2).
Treatment adherence was generally good
The majority (88%) read either all (69%) or more than half
of the booklet (19%); 79% used the relaxation CD, and
76% practiced paced breathing, at least once a week. At
6 weeks, a signiﬁcantly greater reduction in HFNS prob-
lem rating was reported by men who read all of the booklet
compared to those who read less (adjusted mean difference
of 2.78, 95% CI 2.19 to 3.37; p=0.01). No signiﬁcant dif-
ferences were found between men who practised the
relaxation/paced breathing more or less than once a week.
Adverse events, medication changes and use of health
services
Two cases of adverse events unrelated to the intervention
were reported: one participant passed away before the
32-week assessment because of metastatic cancer and
Table 1. Demographic and clinical baseline characteristics (N (%) or mean (SD) with p values for between group comparisons)
CBT (n = 33) TAU (n = 35) p Values
Age at randomisation [years] 67.97 (7.65) 69.71 (7.90) 0.36
Ethnic origin
White 28 (85%) 22 (63%) 0.08
Black 5 (15%) 12 (34%)
Other 1 (3%)
Married/living with partner 25 (76%) 25 (71%) 0.89
Educated beyond 16 years of age 16 (49%) 16 (46%) 0.90
Employed 9 (27%) 6 (17%) 0.48
Mean body mass index (kg/m2; SD) 26.40 (3.79) 27.74 (3.63) 0.16
Cancer type
Localised 16 (49%) 18 (51.5%) 0.91
Locally advanced 7 (21%) 6 (17%)
Metastatic 10 (30%) 11 (31.5%)
Time since prostate cancer diagnosis [months] 24.76 (20.70) 29.57 (34.48) 0.49
Previous treatment history:
Prostatectomy 10 (30%) 8 (23%) 0.49
Radiotherapy 23 (70%) 18 (51%) 0.19
Current hormonal therapy:
Luteinizing/gonadotropin-releasing hormone agonists
Goserelin (zoladex) 23 (70%) 23 (66%)
Leupropelin (prostap) 2 (6%) 5 (14%)
Triptorelin (de-capeptyl) 2 (6%) 2 (6%)
Anti-androgens
Cyproterone acetate (cyprostat) 1 (3%) 0
Bicalutamide (Casodex) 5 (15%) 5 (14%)
Receiving other treatments for HFNS at baseline:
Red clover 3 (9%) 1 (3%)
Fish oils 1 (3%) 0
Ginseng 0 1 (3%)
Evening primrose 0 1 (3%)
Self-efﬁcacy in carrying out treatment 3.51 (1.08) 3.40 (0.93) 0.20
Treatment expectations 3.09 (1.19) 3.05 (0.82) 0.18
Somatosensory Ampliﬁcation Scale 2.47 (0.60) 2.47 (0.59) 0.99
Revised Life Orientation Test 15.96 (4.14) 16.05 (4.18) 0.91
Constructed Meaning Scale 32.18 (6.46) 31.48 (6.29) 0.65
Emotional Control—Barriers to Help Seeking Scale 1.71 (0.76) 2.10 (0.82) 0.06
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another started chemotherapy, and his data was excluded
from further analyses. One participant (CBT) stopped
zoladex injections after his 6-week assessment, and two
(TAU) reported changes between baseline and 6 weeks
(one started zoladex and one radiation therapy). Between
the 6 and 32 weeks, four (CBT) started new medications
for prostate cancer (two casodex, one alpharadin and one
zytiga). There were no signiﬁcant group differences in
attendance at GP, oncologist or nurse specialist between
baseline and 6 weeks or between 6 and 32 weeks.
Discussion
The results of this trial suggest that CBT appears to be a safe
and effective intervention to help prostate cancer patients
undergoing ADT to manage troublesome HFNS. At post-
Table 2. Effect of treatment on hot ﬂushes and night sweats measures: HFNS problem rating, frequency and Beliefs and Behaviours Scale;
HADs and Global QOL (EORTC). SSC= Sternal Skin Conductance
CBT mean (SD) N TAU mean (SD) N Adjusted mean difference (SE) 95% CI
HFNS problem rating
Baseline 4.54 (1.98) 33 4.81 (2.41) 35
6 weeks 2.76 (1.53) 32 4.19 (2.20) 34 1.33 (0.37)**
Effect size partial Eta2 = 0.16
2.07 to0.58
32 weeks 2.66 (1.67) 27 3.33 (1.84) 24 0.7 (0.43) 1.59 to 0.16
HFNS total frequency
Baseline 56.09 (30.16) 33 52.95 (50.07) 35
6 weeks 36.06 (25.03) 32 44.58 (38.70) 34 12.12 (5.14)*
Effect size partial Eta2 = 0.08
22.39 to1.84
32 weeks 32.11 (24.54) 27 42.08 (54.85) 24 12.43 (7.93) 28.38 to 3.52
HF frequency
Baseline 39.18 (24.21) 33 34.94 (39.56) 35
6 weeks 25.56 (18.63) 32 27.47 (23.74) 34 4.97 (4.06) 13.09 to 3.14
32 weeks 19.40 (17.93) 27 29.95 (39.63) 24 12.80 (6.17)* 25.21 to3.86
NS frequency
Baseline 16.90 (14.27) 33 18.01 (13.05) 35
6 weeks 10.50 (9.67) 32 17.11 (18.80) 34 5.79 (2.96) 11.71 to 0.13
32 weeks 12.70 (11.72) 27 12.12 (17.67) 24 0.66 (3.59) 6.56 to 7.88
SSC frequency
Baseline 29.31 (11.73) 23 27.80 (11.63) 21
6 weeks 27.47 (9.99) 20 23.61 (11.98) 12 0.69 (3.19) 5.84 to7.22
HF beliefs/behaviour
Baseline 3.06 (1.00) 33 3.06 (1.18) 33
6 weeks 1.41 (1.08) 30 2.35 (1.12) 27 0.92 (0.20)** 1.34 to0.51
32 weeks 1.57 (1.17) 24 2.09 (0.98) 17 0.49 (0.30) 1.11 to 0.12
Calm acceptance
Baseline 2.62 (0.78) 33 2.75 (0.97) 33
6 weeks 3.58 (1.11) 30 3.81 (0.90) 27 0.29 (0.16) 0.70 to 0.21
32 weeks 4.09 (0.67) 24 3.90 (0.49) 17 0.29 (0.18) 0.07 to 0.66
Humour openness
Baseline 4.22 (1.04) 33 4.07 (1.37) 33
6 weeks 3.58 (1.17) 30 3.02 (0.91) 27 0.56 (0.23)* 0.10 to 1.01
32 weeks 3.55 (1.05) 24 3.52 (0.80) 17 0.20 (0.25) 0.31 to 0.72
HADS depression
Baseline 4.03 (3.57) 33 4.17 (3.27) 33
6 weeks 3.26 (3.40) 30 4.21 (3.46) 27 0.59 (0.67) 1.94 to 0.74
32 weeks 3.61 (3.11) 24 3.16 (2.22) 17 0.52 (0.83) 1.15 to 2.20
HADS anxiety
Baseline 5.06 (2.96) 33 5.28 (3.64) 33
6 weeks 4.70 (3.33) 30 5.14 (4.09) 27 0.15 (0.68) 1.21 to 1.52
32 weeks 4.15 (2.73) 24 4.83 (2.81) 17 0.32 (0.70) 1.75 to 1.10
EORTC global QOL
Baseline 72.22 (17.26) 33 66.16 (16.92) 33
6 weeks 76.19 (20.12) 30 68.26 (19.15) 27 3.61 (4.49) 5.42 to 12.63
32 weeks 75.36 (18.54) 24 70.83 (17.59) 17 0.97 (5.91) 13.01 to 11.01
CBT = Cognitive Behavioural Therapy
TAU = Treatment as usual
*p = 0.05.
**p = 0.001.
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treatment, the CBT group reported less problematic and less
frequent HFNS than the TAU group, with clinically relevant
reductions. At 32 weeks the CBT group maintained their
improvement but group differences did not reach signiﬁ-
cance, largely because of some improvement in the TAU
group. However, the group difference in hot ﬂush (but not
night sweat) frequency remained signiﬁcant at 32 weeks.
At baseline the sample reported frequent (44–58 HFNS
per week) and problematic HFNS, at levels consistent with
previous studies of prostate cancer survivors having ADT
[36,37]. The percentage scoring within the clinical range
for depression and anxiety (HADS) (>/8) were 20% and
25% respectively, higher than that reported in a recent
meta-analysis of prevalence of anxiety (15%) and depres-
sion (15%) in men undergoing treatment for prostate cancer
[38], which might be because they all had HFNS—which
are associated with distress [7]. Their QOL EORTC Global
scores (69.19, SD=17.23) were similar to norms for men
with prostate cancer (68.4, SD=22.2) [39]. The sample
was socially mixed (based on level of education), and co-
morbid health problems were common. Nevertheless, CBT
was effective adjusting for baseline characteristics and re-
gardless of BMI, educational level or cancer type. However,
the intervention did not signiﬁcantly reduce mood or QOL.
Adherence to the CBT was good in terms of reading the
booklet and using the relaxation/paced breathing CD, and
those who read the whole booklet derived more beneﬁt.
We examined potential mediators in order to understand
how the treatment might be working. Although signiﬁcant
improvements in subjective measures were evident, no
group differences in physiologically (SSC) measured
HFNS were found. The concordance between subjective
and physiologically (SSC) measured HFNS is relatively
low in ambulatory settings [35,37], but inclusion of SSC
measures can aid understanding of how treatments are
working. Overall, our results are consistent with ﬁndings
from a CBT trial for HFNS in breast cancer patients
[13], suggesting that CBT might work mainly by affecting
symptom perception and cognitive appraisal of HFNS,
rather than physiological mechanisms [16,23,40]. The
CBT group reported less negative HFNS beliefs and be-
haviours and more humour and openness compared to
TAU at 6 weeks, and change in HFNS negative beliefs
and behaviours (e.g. changes in beliefs about the social
consequences and about sleep, and less avoidance of ac-
tivities) was associated with reduction in problem-rating.
Therefore the intervention appeared to be targeting cogni-
tive and behavioural changes as intended.
Limitations include lack of an attention control arm and
the sample size, particularly for the TAU group at
32 weeks; the sample size was not large enough to examine
all secondary measures, nor to perform a full mediation
analysis. We attempted to reduce bias by masking where
possible, but it is not possible to mask participants in this
type of trial. Additional variables might have affected
HFNS, such as health-related behaviours, e.g. caffeine in-
take, and other speciﬁc health problems. Future research
could test the intervention in a multi-centre trial including
a range of ethnicities, as well as examine speciﬁc compo-
nents of the intervention, such as paced breathing.
In terms of clinical implications, to our knowledge this is
the ﬁrst evaluation of a brief guided self-help CBT interven-
tion for men with HFNS. Adherence to treatment was good,
and the contact/therapist time was on average only 60 min.
The CBT intervention was delivered in a hospital setting,
using standardised materials (treatment booklet, CD) and
could be included within survivorship support programmes.
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